HIVR4P symposia series - Insights in HIV vaccine research

Wed, 11 Oct 2023

7:00 - 8:00pm [CEST]


Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research.

How do you scale up use of CAB-LA and the vaginal ring? What are the latest developments in the quest for an effective HIV vaccine? What role can bNAbs play in HIV cure research? 

You're invited to attend a series of three special virtual symposia in October 2023 that will explore these questions by bringing together the scientific community to address the biggest challenges in biomedical prevention. 

IAS Governing Council and HIVR4P 2024 Organizing Committee members will host the series in which leading experts will preview some of the groundbreaking HIV prevention science you can expect at HIVR4P 2024, the 5th HIV Research for Prevention Conference. 

Register now for free to join us in October 2023!

Implementation and rolling out of CAB-LA
Wednesday, 4 October, 12:00 – 13:00 Peru Time (PET) (19:00 – 20:00 CEST)  

  • Moderator: Mitchell Warren, AIDS Vaccine Advocacy Coalition (AVAC)
  • Presentation 1: CAB-LA for cis and trans women and men who have sex with men. Beatriz Grinsztejn, Fundação Oswaldo Cruz (Fiocruz)
  • Presentation 2: CAB-LA and vaginal ring scale up (civil society perspective). Imelda Mahaka, Pangaea Zimbabwe AIDS Trust (PZAT)
  • Live Q&A with the audience

Insights into HIV vaccine research
Wednesday, 11 October, 12:00 – 13:00 PET (19:00 – 20:00 CEST)  

  • Moderator: Susan Buchbinder, University of California
  • Presentation 1: Looking back on the Mosaico study. Jorge Sanchez, Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, UNMSM
  • Presentation 2: Novel vaccine platforms. Devin Sok, International AIDS Vaccine Initiative (IAVI)
  • Live Q&A with the audience

The future of bNAbs
Monday, 16 October, 12:00 – 13:00 PET (19:00 – 20:00 CEST) 

  • Presentation 1: Requirements for bNAbs in HIV prevention. Florian Klein, University of Cologne
  • Presentation 2: Affordability and economic implications for bNAbs. Jayasree Iyer, Access to Medicine Foundation
  • Live Q&A with the audience


    Register now


      The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.